Fermenta Biotech Ltd
Established in 1951, DIL Limited (earlier known as Duphar-Interfran Limited) is a publicly-listed company that has developed a unique standing in the businesses of pharmaceuticals, biotechnology, environmental solutions and other segments.(Source : 201983 Annual Report Page No: 6)
- Market Cap: 571.55 Cr.
- Current Price: 582.60
- 52 weeks High / Low 1125.00 / 577.00
- Book Value: 304.54
- Stock P/E: 5.25
- Dividend Yield: 0.20 %
- ROCE: 42.01 %
- ROE: 64.55 %
- Sales Growth (3Yrs): 37.62 %
- Listed on BSE
- Company Website
- Face Value: 5.00
Pros:
Company has good consistent profit growth of 74.31% over 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 30.43%
Debtor days have improved from 80.50 to 59.29 days.
Cons:
Tax rate seems low
** Remarks:
Some businesses are provided tax benefits to encourage their development
Peer Comparison Sector: Pharmaceuticals // Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results Consolidated Figures in Rs. Crores / View Standalone
Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
38 | 44 | 44 | 64 | 98 | 97 | 80 | 121 | 112 | 92 | 81 | 81 | |
38 | 39 | 42 | 50 | 59 | 59 | 54 | 77 | 67 | 61 | 57 | 65 | |
Operating Profit | -0 | 5 | 2 | 13 | 40 | 38 | 26 | 44 | 45 | 31 | 25 | 16 |
OPM % | -1% | 12% | 4% | 21% | 40% | 39% | 32% | 37% | 40% | 34% | 30% | 19% |
Other Income | 1 | 0 | 0 | 4 | 0 | 4 | 3 | 9 | 1 | 1 | 3 | 5 |
Interest | 2 | 2 | 3 | 4 | 2 | 4 | 4 | 5 | 6 | 6 | 5 | 5 |
Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 4 |
Profit before tax | -4 | 0 | -3 | 11 | 34 | 35 | 22 | 46 | 37 | 23 | 19 | 12 |
Tax % | 0% | 239% | -9% | 40% | 23% | 24% | 24% | 25% | 25% | -65% | 26% | -168% |
Net Profit | -4 | -2 | -4 | 4 | 19 | 16 | 15 | 32 | 26 | 37 | 13 | 33 |
EPS in Rs | -4.73 | -2.20 | -4.38 | 7.27 | 20.62 | 4.33 | 18.03 | 34.84 | 28.25 | 40.59 | 14.21 | 33.99 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss Consolidated Figures in Rs. Crores / View Standalone
Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
52 | 67 | 68 | 76 | 119 | 117 | 139 | 142 | 155 | 164 | 302 | 403 | 365 | |
42 | 57 | 53 | 57 | 88 | 94 | 112 | 126 | 134 | 152 | 209 | 248 | 249 | |
Operating Profit | 11 | 10 | 15 | 19 | 31 | 23 | 27 | 16 | 20 | 12 | 93 | 155 | 116 |
OPM % | 20% | 15% | 22% | 25% | 26% | 20% | 20% | 11% | 13% | 7% | 31% | 38% | 32% |
Other Income | 2 | 4 | 6 | 23 | 14 | 2 | 2 | 0 | 1 | 3 | 9 | 6 | 11 |
Interest | 1 | 3 | 2 | 1 | 4 | 5 | 5 | 4 | 6 | 10 | 14 | 21 | 21 |
Depreciation | 4 | 5 | 4 | 4 | 8 | 9 | 10 | 9 | 8 | 10 | 12 | 12 | 13 |
Profit before tax | 7 | 6 | 15 | 36 | 33 | 10 | 14 | 3 | 7 | -6 | 76 | 129 | 92 |
Tax % | 7% | 28% | 22% | 23% | 19% | 36% | 24% | 67% | 61% | -49% | 28% | 8% | |
Net Profit | 7 | 6 | 12 | 25 | 22 | 4 | 8 | 0 | -1 | -11 | 34 | 110 | 109 |
EPS in Rs | 7.19 | 5.73 | 11.90 | 26.55 | 22.98 | 3.60 | 8.14 | 0.25 | 0.00 | 0.00 | 36.65 | 120.31 | 117.04 |
Dividend Payout % | 33% | 59% | 30% | 23% | 31% | 124% | 29% | 249% | -51% | -5% | 2% | 1% |
* Sales is net of excise duty and discounts
Compounded Sales Growth | |
---|---|
10 Years: | 19.63% |
5 Years: | 23.73% |
3 Years: | 37.62% |
TTM: | -7.96% |
Compounded Profit Growth | |
---|---|
10 Years: | 34.65% |
5 Years: | 74.31% |
3 Years: | 377.21% |
TTM: | 32.55% |
Stock Price CAGR | |
---|---|
10 Years: | 23.61% |
5 Years: | 29.57% |
3 Years: | 45.66% |
1 Year: | -40.63% |
Return on Equity | |
---|---|
10 Years: | 14.59% |
5 Years: | 19.12% |
3 Years: | 30.43% |
Last Year: | 64.55% |
Balance Sheet Consolidated Figures in Rs. Crores / View Standalone
Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Sep 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 5 | 5 | |
Reserves | 75 | 77 | 85 | 113 | 127 | 125 | 130 | 129 | 128 | 142 | 122 | 228 | 294 |
Borrowings | 12 | 18 | 14 | 20 | 37 | 43 | 65 | 71 | 89 | 87 | 173 | 212 | 213 |
24 | 25 | 21 | 38 | 52 | 57 | 63 | 62 | 72 | 80 | 87 | 111 | 120 | |
Total Liabilities | 113 | 123 | 121 | 173 | 218 | 228 | 261 | 264 | 290 | 312 | 385 | 555 | 631 |
40 | 53 | 39 | 46 | 73 | 94 | 87 | 85 | 168 | 172 | 177 | 178 | 195 | |
CWIP | 8 | 4 | 7 | 14 | 13 | 15 | 36 | 65 | 6 | 5 | 4 | 22 | 50 |
Investments | 20 | 18 | 27 | 41 | 18 | 11 | 17 | 18 | 15 | 18 | 10 | 8 | 8 |
46 | 48 | 48 | 72 | 115 | 107 | 120 | 96 | 101 | 116 | 193 | 348 | 377 | |
Total Assets | 113 | 123 | 121 | 173 | 218 | 228 | 261 | 264 | 290 | 312 | 385 | 555 | 631 |
Cash Flows Consolidated Figures in Rs. Crores / View Standalone
Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
10 | 8 | 2 | -1 | 39 | 23 | 14 | 15 | 4 | 2 | 59 | 90 | |
-19 | -13 | 2 | -7 | -50 | -20 | -25 | -18 | -13 | 7 | -101 | -97 | |
13 | 4 | -5 | 16 | 7 | -8 | 13 | 1 | 10 | -12 | 89 | 12 | |
Net Cash Flow | 3 | -0 | -1 | 8 | -4 | -4 | 2 | -2 | 1 | -4 | 47 | 6 |
Ratios Consolidated Figures in Rs. Crores / View Standalone
Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 10% | 10% | 17% | 19% | 18% | 9% | 10% | 4% | 6% | 2% | 34% | 42% |
Debtor Days | 98 | 76 | 64 | 81 | 72 | 79 | 106 | 91 | 101 | 99 | 83 | 59 |
Inventory Turnover | 6.99 | 8.51 | 8.89 | 8.42 | 7.39 | 5.00 | 5.73 | 6.29 | 6.24 | 4.91 | 6.71 | 5.81 |
Recent Announcements
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Dec. 10, 2019
- Announcement under Regulation 30 (LODR)-Investor Presentation Dec. 6, 2019
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Dec. 6, 2019
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Dec. 2, 2019
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Nov. 20, 2019
Annual Reports
- Financial Year 2019 from bse
- Financial Year 2018 from bse
- Financial Year 2017 from bse
- Financial Year 2016 from bse
- Financial Year 2015 from bse
- Financial Year 2014 from bse
- Financial Year 2013 from bse
- Financial Year 2012 from bse
- Financial Year 2011 from bse
- Financial Year 2010 from bse
Credit Ratings
- Fermenta Biotech Limited care
- Fermenta Biotech Limited: Ratings Withdrawn crisil
- Fermenta Biotech Limited: Ratings Continues on 'Watch Developing' crisil
- Fermenta Biotech Limited: Ratings Continues on 'Watch Developing' crisil
- Fermenta Biotech Limited care
- DIL Limited: Issuer not cooperating, based on best-available information; Rating revised to 'Watch with Developing Implications Issuer not cooperating'; Rating withdrawn crisil
- DIL Limited care
- Fermenta Biotech Limited care
- DIL Limited care
- DIL Limited care
- Fermenta Biotech Limited care